Forge Therapeutics is a biotechnology company founded in 2013 with a focus on discovering and developing innovative treatments targeting metalloproteins. The company's proprietary approach merges the study of metals in biology with medicinal chemistry, enabling the creation of selective inhibitors for this extensive class of targets.
With the slogan "Harnessing the power of chemistry for innovative therapies targeting metalloproteins," Forge Therapeutics has positioned itself at the forefront of the Biotechnology, Health Care, and Health and Wellness industries.
The company's most recent investment was a significant $5.70 million grant from CARB-X, received on 03 January 2019.